The Claim
In non-diabetic adults with overweight or obesity, once-weekly subcutaneous semaglutide at a dose of 2.4 mg, when combined with lifestyle intervention, results in a mean body weight reduction of 14.9% over 68 weeks, which is 12.4 percentage points greater than placebo plus lifestyle intervention, with 86.4% of participants achieving at least 5% weight loss and 50.5% achieving at least 15% weight loss, indicating clinically meaningful and sustained efficacy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For adults who aren't diabetic but carry extra weight, a weekly injection of semaglutide (2.4 mg) plus healthy lifestyle changes led to nearly 15% weight loss over a year and a half—way more than lifestyle changes alone.
See the scientific wording
In non-diabetic adults with overweight or obesity, once-weekly subcutaneous semaglutide at a dose of 2.4 mg combined with lifestyle intervention causes a mean body weight reduction of 14.9% over 68 weeks, which is 12.4 percentage points greater than placebo plus lifestyle intervention, with 86.4% of participants achieving at least 5% weight loss and 50.5% achieving at least 15% weight loss, demonstrating clinically meaningful and sustained efficacy.
What the research says
1 studyStudy: Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The study tested the exact same drug, dose, and treatment plan described in the claim and found the same weight loss results, so it supports the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.